Expanded MRD analysis of phase 3 CEPHEUS (395 transplant-ineligible/deferred newly diagnosed myeloma): D-VRd vs VRd gave higher MRD negativity at 10⁻⁵ (60.9% vs 39.4%; OR 2.37) at median 58.7 months. PFS in MRD-negative patients was non-significant (HR 0.61).
RCTn = 395
Zweegman et al. Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS